- Home
- MYI vs PRME Comparison
MYI vs PRME Comparison
Compare MYI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- PRME
- Stock Information
- Founded
- MYI 1992
- PRME 2019
- Country
- MYI United States
- PRME United States
- Employees
- MYI N/A
- PRME 214
- Industry
- MYI Investment Bankers/Brokers/Service
- PRME Medicinal Chemicals and Botanical Products
- Sector
- MYI Finance
- PRME Health Care
- Exchange
- MYI Nasdaq
- PRME Nasdaq
- Market Cap
- MYI 701.9M
- PRME 693.5M
- IPO Year
- MYI N/A
- PRME 2022
- Fundamental
- Price
- MYI $11.03
- PRME $4.09
- Analyst Decision
- MYI
- PRME Buy
- Analyst Count
- MYI 0
- PRME 6
- Target Price
- MYI N/A
- PRME $8.88
- AVG Volume (30 Days)
- MYI 256.7K
- PRME 2.9M
- Earning Date
- MYI 01-01-0001
- PRME 11-11-2025
- Dividend Yield
- MYI 4.81%
- PRME N/A
- EPS Growth
- MYI N/A
- PRME N/A
- EPS
- MYI N/A
- PRME N/A
- Revenue
- MYI N/A
- PRME $4,961,000.00
- Revenue This Year
- MYI N/A
- PRME $179.58
- Revenue Next Year
- MYI N/A
- PRME N/A
- P/E Ratio
- MYI N/A
- PRME N/A
- Revenue Growth
- MYI N/A
- PRME 739.42
- 52 Week Low
- MYI $9.32
- PRME $1.11
- 52 Week High
- MYI $11.70
- PRME $5.17
- Technical
- Relative Strength Index (RSI)
- MYI 77.60
- PRME 58.58
- Support Level
- MYI $10.54
- PRME $3.09
- Resistance Level
- MYI $11.04
- PRME $4.18
- Average True Range (ATR)
- MYI 0.08
- PRME 0.27
- MACD
- MYI 0.05
- PRME 0.08
- Stochastic Oscillator
- MYI 95.18
- PRME 88.53
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.